Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F14%3A%230000170" target="_blank" >RIV/26475821:_____/14:#0000170 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/14:10271883 RIV/00669806:_____/14:10271883

Výsledek na webu

<a href="http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1578&id=17234" target="_blank" >http://www.tumorionline.it/articoli.php?archivio=yes&vol_id=1578&id=17234</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1700/1578.17234" target="_blank" >10.1700/1578.17234</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report

Popis výsledku v původním jazyce

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation.

Název v anglickém jazyce

Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report

Popis výsledku anglicky

Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used for the treatment of advanced stage non-small cell lung cancer (NSCLC). Clinical trials have shown high efficacy of erlotinib, particularly in patients harboring activating mutations in the EGFR gene. Here we describe the case of a 42-year-old female light smoker diagnosed with EGFR mutation-positive adenocarcinoma of the left lung with pleural metastases, pleural effusion and metastases to the thoracic vertebrae (stage IV, T4NXM1). Although the patient developed resistance to erlotinib in the first line, she achieved disease stabilization lasting for 13 months as a response to erlotinib retreatment after 6 cycles of second-line chemotherapy. In conclusion, retreatment with erlotinib in our patient was effective. Therefore it should be considered as a good treatment option for patients with NSCLC harboring EGFR mutation.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR9087" target="_blank" >NR9087: Využití molekulárních prediktorů pro optimální selekci cílené léčby nemalobuněčného karcinomu plic</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Tumori

ISSN

0300-8916

e-ISSN

—

Svazek periodika

100

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

4

Strana od-do

70-73

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—